Invitation to Sponsor

On behalf of the Epilepsy Society of Australia, I have great pleasure in inviting you to sponsor or exhibit at the 38th Annual Scientific Meeting, which will be held 6 - 8 November 2024 in Hobart, Tasmania.

We anticipate that the meeting will attract about 250 delegates from around Australia and South-East Asia, including trainees, practising neurologists, technologists, scientists, nurses and allied health professionals, providing a great opportunity for networking and exchange of information.

As in previous years, the success of the ESA Annual Scientific Meeting has in large part come from the support of our partners in industry, providing sponsorship towards speaker and meeting costs.

This is also an excellent opportunity for sponsors to promote their products and services to key industry decision makers in Australia, and to make contact with a select and valuable audience.

We look forward to welcoming you to Hobart for the ESA ASM 2024, and working with you to maximise the promotional benefits to your company from the meeting.

Dean Jones & Tyson Ware

Co-Chairs, ESA Annual Scientific Meeting Committee

and

Stephen Malone
ESA President, 2024

Download Sponsorship and Exhibition Prospectus

UCB aspires to be the patient-centric global biopharmaceutical leader, transforming the lives of people with severe diseases. At UCB our sense of purpose is to help people suffering from severe central nervous system disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by patients’ needs.

Jazz Pharmaceuticals is a global Biopharmaceutical Company whose purpose is to transform the lives of patients and their families through innovation. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options so they can live their lives more fully. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late stage development, in Neuroscience and Haematology/Oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz Pharmaceuticals has employees around the globe including Australia and New Zealand, serving patients in nearly 75 countries.